Real world data essential for CAR-T therapy success

Innovators will need to quantify value to bring costly drugs to market.
The post Real world data essential for CAR-T therapy success appeared first on Pharmaphorum.

Filed under: Cancer, Immunotherapy

Pfizer spinoff Zoetis ups 2017 guidance, eyes more M&A for future growth

What does Pfizer animal health spinoff Zoetis share with its former parent, aside from its lineage? They’re both under pressure from investors to drive growth through acquisitions. Zoetis met second-quarter expectations and brightened its forecast for the rest of the year, and now it’s looking to M&A to drive further growth.

Filed under: Company

Takeda begins new R&D link-up with Molecular Templates

Takeda is increasing its R&D investment in oncology with a collaboration with Texas biotech Molecular Templates. The Japanese
The post Takeda begins new R&D link-up with Molecular Templates appeared first on Pharmaphorum.

Filed under: R&D

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

Filed under: Cancer, Immunotherapy

Bristol─Myers Squibb’s Orencia receives European approval for active psoriatic arthritis treatment

Bristol─Myers Squibb Company announced that the European Commission (EC) has approved Orencia alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult

Filed under: Arthritis

GSK looks to exit rare diseases

The British drugmaker is putting its rare disease business up for sale amid a company-wide refocusing.

Filed under: Company

Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies

SAN JUAN, Puerto Rico, July 27, 2017 /PRNewswire/ — Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ: BIIB) for select products in…

Filed under: MS

Lilly puts two-thirds of mid-phase cancer pipeline up for sale in major shake up of R&D priorities

Eli Lilly is seeking partners for two-thirds of its mid-phase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to mid-stage assets it thinks can become the new standard of care.

Filed under: Company

Second US infliximab biosimilar launched at 35% discount to J&J’s Remicade

Merck & Co. will challenge both reference drugmaker J&J and fellow biosimilar developer Pfizer through its version of Remicade, Renflexis.

Filed under: Biosimilar

New Gene Discoveries Could Redefine Alzheimer’s Treatment

ArticleDeveloping a potent therapy for Alzheimer’s disease will be one of the biggest healthcare challenges over the next few decades. Staff Author: Ryan BusheyTopics: Life Sciences

Filed under: Alzheimer’s

Diabetes drugmakers partner with mobile startups to boost patient engagement

Novo Nordisk and Roche are two examples of drugmakers that are turning to digital-health startups to better engage with patients and mine valuable real-world evidence.

Filed under: Diabetes

Theravance COPD drug clears safety study, setting up NDA

Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data. The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.

Filed under: COPD

Gilead’s latest hep C combo approved in US

Vosevi is aimed at tough to treat patients.
The post Gilead’s latest hep C combo approved in US appeared first on Pharmaphorum.

Filed under: HCV

Eli Lilly licenses Adimab antibody discovery and optimization tech

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.

Filed under: R&D

Add-on azithromycin cuts asthma exacerbations

FROM THE LANCET Adults with persistent symptomatic asthma who took azithromycin as an add-on therapy experienced fewer exacerbations and had …

Filed under: Respiratory

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development.

Filed under: Inflammatory

5 trends shaping Alzheimer’s drug development

Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned.

Filed under: Alzheimer’s

FDA panel backs Novartis’ CAR-T therapy CTL019

Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.

Filed under: Cancer, Immunotherapy

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions

Filed under: Company

Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs

Read recent commentaries about drug-cost issues.

Filed under: Pricing